- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% | 1 | MarketBeat | ||
| 14.11. | Enliven Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
| 14.11. | Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02 | 2 | Seeking Alpha | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 20 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains... ► Artikel lesen | |
| 30.10. | Enliven Therapeutics CFO Benjamin Hohl verkauft Aktien im Wert von 178.484 US-Dollar | 2 | Investing.com Deutsch | ||
| 30.10. | Enliven Therapeutics gets Buy rating, $36 target from Jones Trading | 1 | Investing.com | ||
| 22.10. | Finanzvorstand von Enliven Therapeutics verkauft Aktien im Wert von 24.422 US-Dollar | 1 | Investing.com Deutsch | ||
| 22.10. | Enliven Therapeutics COO Anish Patel verkauft Aktien im Wert von 21.482 US-Dollar | 1 | Investing.com Deutsch | ||
| 22.10. | Enliven Therapeutics CEO Kintz verkauft Aktien im Wert von 27.722 US-Dollar | 1 | Investing.com Deutsch | ||
| 22.10. | Wissenschaftlicher Leiter von Enliven Therapeutics verkauft Aktien im Wert von 25.412 US-Dollar | 1 | Investing.com Deutsch | ||
| 18.10. | ELVN stock soars to 52-week high, reaching $28.66 | 1 | Investing.com | ||
| 18.10. | ELVN-Aktie erreicht 52-Wochen-Hoch bei 28,66 US-Dollar | 1 | Investing.com Deutsch | ||
| 07.10. | Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy? | 2 | MarketBeat | ||
| 01.10. | Enliven Therapeutics-Aktie behält Outperform-Bewertung von Mizuho nach positiven Studiendaten | 2 | Investing.com Deutsch | ||
| 01.10. | Enliven Therapeutics shares maintain Outperform rating from Mizuho with positive trial data | 2 | Investing.com | ||
| 29.09. | Enliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia Patients | 3 | RTTNews | ||
| 28.09. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia | 2 | GlobeNewswire (USA) | ||
| 23.09. | Mizuho maintains Outperform rating on Enliven Therapeutics stock | 1 | Investing.com | ||
| 23.09. | Mizuho hält an Outperform-Bewertung für Enliven Therapeutics-Aktie fest | 1 | Investing.com Deutsch | ||
| 18.09. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML | 6 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,086 | -1,97 % | Valneva mit Shigella-News: Bringt das die Wende? | Die Valneva Aktie erhielt gestern dringend benötigte Impulse, nachdem sie zuletzt tief gefallen war und zwei Tage in Folge Tagestiefs bei 2,232 bzw. 2,240 Euro markierte. Gestern konnte die Aktie im... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| BIOFRONTERA | 2,845 | +6,16 % | Biofrontera's listed shares fall as Q3 revenue misses estimates | ||
| CRISPR THERAPEUTICS | 44,900 | 0,00 % | CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? | ||
| DEFENCE THERAPEUTICS | 0,364 | -1,62 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| BLUEBIRD BIO | 0,284 | -0,18 % | bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September... ► Artikel lesen | |
| AFFIMED | 2,610 | -0,38 % | Affimed N.V.: Affimed Reports Third Quarter 2024 Financial Results & Business Update | AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to January 31, 2025.Accordingly... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,100 | +0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| DENALI THERAPEUTICS | 23,330 | +0,65 % | Denali Therapeutics Inc. - 8-K, Current Report | ||
| FATE THERAPEUTICS | 2,027 | -3,57 % | Fate Therapeutics, Inc.: Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| CELLECTIS | 1,718 | -1,83 % | Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 | UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs - one allogeneic... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,480 | 0,00 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| AGIOS | 49,400 | -5,00 % | Agios Pharmaceuticals, Inc.: Agios Reports Business Highlights and Third Quarter 2024 Financial Results | - Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025 - - Received $1.1 Billion in Payments from Royalty Pharma... ► Artikel lesen |
Das Unternehmen ENLIVEN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 25,450 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.
